The five-year survival rate was 97%. Since most of the patients are in reproductive age radiation exposure of the remaining testicle is an important aspect to be considered. In this connection, phantom and in vivo measurements by means of a thermoluminiscence dosimetry system were made. Simulation of a dorsoventral treatment using a sagittal view made evident that without a goqadal shield the dose 6 cm outside the field boundary amounts to 5% of the total dose. This means, considering the treatment of the paraaortal and i liacal nodes with 3000 cGy it corresponds to a gonadal dose of 150 cGy. In vivo measurements were made to find out the dose reduction while using a capsule consisting of 20 mm woodmetal. Exposure of the remaining testicle was as follows: Prognosis of primary extragonadal germ cell tumor is reported as being less favorable than that of gonadal tumor because of diagnostic difficulties resulting in high tumor burden at start of therapy. We report our experience with 16 pts with primary extragonadal germ cell tumor. 14 pts had nonseminomatous and 2 seminomatons tumors, in 6 cases tumormarkers AFP and/or hCG were in part extremely elevated . All had lymphnode involvement: 6 retroparltoneal, 7 mediastinal/cervical, and 3 both -diameter exceeding 10cm in 8/16 pts. Organ metastases were found in 6 pts (4 only lung, 2 concomitant liver and bone). Treatment consisted of Cisplatinum/Vinblastine/Bleomycin (PVB) in 9 cases, Vinblastine/Ifosfamide/Platinum (VIP) in 3 cases, Etoposide/Cisplatinum/Bleomycin/Cyclophosphamide (ECBC) in 2 cases; 2 pts were treated only with Vinblastine/Bleomycin because of intensive myelosuppression due to prior radiotherapy. Complete remission was reached in 7/14 nonseminomatous pts (50%) and 2/2 seminoma pts with duration from 12+ to 68+ months (median 33~ months). I pt with nonseminomatous tumor had a relapse after 36 months of CR. At the time of relapse lymphnode metastases were found in retroperitoneum from a newly developed gonadal tumor in the left testicle (pure seminoma). In all other cases no testicular tumor was found at the time of diagnosis and during follow up sonography. 7/14 nonseminomatous pts had progressive disease, all but one had bulky tumor. In 5 cases start of adequate therapy was delayed up to 7 months. In conclusion the prognosis of extragonadal germ cell tumor is not as good as in the cases of gonadal tumor but improved diagnosis and intensification of primary chemotherapy will produce better results in the near future.
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RELAPSE OF NC~~ TE~FI(]JLAR CANCER (NS(LT) kFl~ (I]~LEIZ RE-MISSICN INIL[ZD BY CHE~JIH~t~mf (III-IV) OR BY SURGN{Y ATONE (I-II B). W. Mair, Ca. Clenm, H. ]9~rhart, G. Staehler and W. Wilmaans
The group treated with chemotherapy consisted of 149 pts. (III-IV). ill pts. = 75% reached (]{, by chemotherapy (PVB). 13 pts. = 12% relapsed after disease free intervall of r = 4-15 months (m = 7). At pr~ diagnesis 1 pt. had stage Ill and 12 pts. stage IV. 6 pts~ 5~ had extesded disense. 3 pts. had metastases in more than 1 localisation. Both tumouzTmrkers AFP and B-EgG were elevated in 5 pts. In 7 pts. the chemotherapy was modified: nminly dese-reductian, prolongation of therapy-intervsll and insufficient chemotherapy without cisplatin~n (3 pts.) . In relapse 6 pts. had clinical symptoms. In the other 7 pts. the relapse was diagnosed by technical investigations, The relapse was treated with (NSradiation in 4 cases, chemotherapy in i0 cases. Objective response was observed in 9 pts. = 69%0:2 pts. had PR = 15%: 7 pts. had OR = 54%. Duration of response (months): m = 18 +, r = 1+-64 +. The group trested with surger~ alone consisted of 39 pts,, of ~:om 18 pts. relapsed. Primary stage of disease was surgically dantmented stage I in 9 pts..In the other 9 pts. only 3 pts. bad surgically deeu~ented lymphnode-involvement (pNl). 3 pt_~. were primary treated with r~dJation after surgery. Relapse-free-intervall (months) r-J+-64, nm9. Sites of relapse were abd. lymphnodes in 6 pts., lung in 6 pts. and both in 3 pts. Tuno~er elevation was found in ii pts. (in 3 pts. = first sign of refmpse). The 18 pts. i~ reTa'F~e were treated with chem0tberapy (Fv~) followad by secandary thoracotcmy in 5 pts. 2 pts. had PD and 1 pt. wan not evaluable for response. Duratien of OR (month): r=6+-76 +, m=36 +. Conclusion: The response-rate of turour-re]apse In the group with initial chemotherapy (54%) is significantly lower than in the other group (83%). Besides the large turourburdes, chemotherapy~ToJifications seem to have a negative effect. Important is the high incidence of brain-metastases in pts. with bulky-disease. In the group without primary chsmtherapy the relalme-free-intervall seems to he longer. This may be one cause for a better response, but the OR-rate of 83% is not sufficient. Exact surgical staging, complete and precise ~tisn during a follow-up progranm (for more than 5 years) ere needed to improve the prognoses up to the leveX of nearly 100%, ~tich is reported for adjuvant chemotherapy. In view of the high curability of early stage non-seminomatous testicular germ cell tumor being achieved today,efforts must be made to decrease the morbidity of current treatment regimens. Preliminary results are presented of a randomized multicenter trial which is to investigate the necessary extend -if any -of adjuvant chemotherapy in stage IIA (solitary retroperitoneal LN-metastasisg 2 cm) and stage lIB (retroperitoneal LN-metastases< 5 cm, resectable). Post-RLND pts. are randomized to observation vs. 2 courses PVB(1) in stage llA, and to 2 vs. 4 courses PVB in stage lIB (2, 3) . Between IV/82-VII/85, 43 pts. IIA and 156 pts. lIB have entered the protocol. 31 and 117 pts. resp. have been followed for 3-24 months (median 13.5-16 mo.). One IIA pt. (observation arm) and 2 lib pts. (with 2 courses PV8) have relapsed. One pt. died of pneumonia after I course PVB. Toxicity was tolerable in 80 % of pts. receiving 2 courses and in 47 % of pts. scheduled to receive 4 courses. In most cases dose reductions were based on subjective sideeffects, not on objective toxicity.
